literature

HIV mutation literature information.

N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.

PMID: 20160634 2010 AIDS (London, England)

Introduction: N348I appears early in therapy and was found to be highly associated with TAMs, M184V/I and the NNRTI resistance mutations K103N, Y181C/I, and G190A/S.

Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.

PMID: 20163340 2010 Current HIV research

Abstract: The most common etravirine resistance associated mutations were Y181C (42.9%), G190A (25.3%), H221Y (19.8%), A98G (18.7%), K101E (16.5%), and V90I (12.1%).

Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.

PMID: 20181911 2010 Journal of clinical microbiology

Abstract: Nevirapine-resistant HIV-1 genotypes (with the mutations K103N, Y181C, and/or G190A) from 21 women were evaluated 10 days and 6 weeks after sdNVP administration and at the initiation of ART.

Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.

PMID: 20188624 2010 Journal of clinical virology

Abstract: Common ETV-RAMs included Y181C (27%), G190A (17%), and K101E (10%).

Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).

PMID: 20236364 2010 HIV medicine

Abstract: Frequent RAMs were Y181C, G190A, K101E and A98G, whereas V179F, Y181V and G190S appeared in <5% of sequences.

Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.

PMID: 20377404 2010 Clinical infectious diseases

Abstract: One hundred copies of each patient's HIV-1 DNA were tested for NVP-resistance point-mutations (K103N, Y181C, and G190A) with a sensitive oligonucleotide ligation assay that was able to detect mutants even at low concentrations (> or = 5% of the viral population).

Abstract: RESULTS: At initiation of NVP-ART, resistance mutations were identified in 38 (26%) of 148 participants given sdNVP (K103N in 19 [13%], Y181C in 8 [5%], G190A in 28 [19%], and > or = 2 mutations in 15 [10%]), at a median 9.3 months after receipt of sdNVP.

Method: Banked plasma-poor whole blood specimens collected from women immediately prior to initiating NVP-ART were retrospectively assessed for three HIV-1 pol mutations conferring high-level resistance to ne

[Evolution of HIV-1 drug resistance in patients failing combination antiretroviral therapy].

PMID: 20450778 2010 Zhonghua yi xue za zhi

Abstract: K103N, G190A, Y181C, K101P, M184V, D67N, K70R, T215Y and K219 were most common mutations.

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.

PMID: 20462946 2010 The Journal of antimicrobial chemotherapy

Abstract: Twenty-nine pairs of NNRTI-selected mutations covaried significantly, including Y181C with seven other mutations (A98G, K101E/H, V108I, G190A/S and H221Y), L100I with K103N, and K101P with K103S.

Result: Among the sequences from 782 women treated with a single dose of nevirapine, the most frequently observed mutations were K103N (28%), Y181C (15%), Y188C (6%), G190A (5%) and E138A (4%).

Result: Fig

Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study.

PMID: 20532178 2010 PloS one

Result: Sixteen subjects (11.3%) had non-nucleoside reverse transcriptase inhibitor (NNRTI) TDR; of these, 15 had one or more of K103N, Y181C/I or G190A/E.

Table: G190A

Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.

PMID: 20535242 2010 Letters in drug design & discovery

Introduction: Mutations associated with resistance to NNRTIs include L100I, K101E, K103N, V106A, V108I, V179D, Y181C, Y188C/L/H, G190A/E/S, M230L, P236L and Y318F.

Browser Board

Co-occurred Entities

Filtrator